{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:16:49Z","timestamp":1783199809418,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2026.02.012","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:05:47Z","timestamp":1772100347000},"page":"628-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positron Emission Tomography\/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"given":"Heidemarie","family":"Ofner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Einspieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ozenil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens P.","family":"Spielvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilva Kristiana","family":"Langrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Bamminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Hassler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal A.T.","family":"Baltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazan","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.02.012_b0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.02.012_b0010","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.02.012_b0015","unstructured":"CDC. Prostate cancer incidence by stage at diagnosis. United States cancer statistics. February 4, 2025. https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/prostate-cancer.html."},{"key":"10.1016\/j.euo.2026.02.012_b0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.012_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.012_b0030","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.02.012_b0035","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.012_b0040","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3390\/jcm14082565","article-title":"Advances in current treatment paradigms for metastatic hormone-sensitive prostate cancer","volume":"14","author":"Smani","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2026.02.012_b0045","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.02.012_b0050","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.02.012_b0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2026.02.012_b0060","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.02.012_b0065","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.3390\/cancers14235922","article-title":"Clinical application of poly(ADP-ribose) polymerase (PARP) inhibitors in prostate cancer","volume":"14","author":"Inderjeeth","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2026.02.012_b0070","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41391-023-00764-1","article-title":"Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases","volume":"27","author":"Shui","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.02.012_b0075","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.annonc.2025.05.534","article-title":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","volume":"36","author":"Olmos","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.02.012_b0080","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.02.012_b0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.02.012_b0090","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.02.012_b0095","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11307-022-01746-w","article-title":"Pilot study: PARP1 imaging in advanced prostate cancer","volume":"24","author":"Dehdashti","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.euo.2026.02.012_b0100","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1158\/1078-0432.CCR-19-3484","article-title":"Safety and feasibility of PARP1\/2 imaging with 18F-PARPi in patients with head and neck cancer","volume":"26","author":"Sch\u00f6der","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.02.012_b0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11307-015-0904-y","article-title":"Non-invasive PET imaging of PARP1 expression in glioblastoma models","volume":"18","author":"Carney","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.euo.2026.02.012_b0110","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00259-025-07448-z","article-title":"Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [18F]PARPi and [68Ga]PSMA PET\/CT?","volume":"53","author":"Einspieler","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.02.012_b0115","article-title":"Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET\/MR","volume":"2","author":"Young","year":"2020","journal-title":"Neuro-Oncol Adv"},{"key":"10.1016\/j.euo.2026.02.012_b0120","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/1078-0432.CCR-22-1602","article-title":"[18F]FluorThanatrace ([18F]FTT) PET imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer, a pilot study","volume":"29","author":"Pantel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.02.012_b0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s43856-025-00791-0","article-title":"[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer","volume":"5","author":"Gitto","year":"2025","journal-title":"Commun Med"},{"key":"10.1016\/j.euo.2026.02.012_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"Agarwal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.02.012_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.euo.2026.02.012_b0140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.02.012_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181847","article-title":"Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET\/CT","volume":"12","author":"Lensen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2026.02.012_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187995","article-title":"Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: implications for cardiovascular risk stratification and clinical trials","volume":"12","author":"Ahlman","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2026.02.012_b0155","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1007\/s00259-022-05817-6","article-title":"Joint EANM\/SIOPE\/RAPNO practice guidelines\/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0","volume":"49","author":"Piccardo","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.02.012_b0160","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/14737159.2023.2287503","article-title":"Molecular imaging of PARP in cancer: state-of-the-art","volume":"23","author":"Filippi","year":"2023","journal-title":"Expert Rev Mol Diagn"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:42:58Z","timestamp":1783197778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931126000490"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.012","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positron Emission Tomography\/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}